On July 21, 2026, Zhuhai Trinomab Pharmaceutical Co., Ltd. (Stock Abbreviation: Trinomab, Stock Code: 688806) officially listed on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange, marking its entry into a brand-new stage of capitalization and high-quality development! Trinomab's first core benchmark product to achieve commercialization—the new generation "tetanus shot," Siltartoxatug Injection—features rapid onset, comprehensive protection duration, and potent neutralization of tetanus toxin. It requires no skin testing and provides complete protection in a single dose! It is the world's first (First-in-Class) fully human anti-tetanus monoclonal antibody and the first domestic innovative biologic in the anti-infective field to be granted Breakthrough Therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The emergence of the anti-tetanus monoclonal antibody has broken the century-old reliance on blood-derived products for passive tetanus immunization.

Government officials, shareholder representatives, intermediary institutions, clients, Trinomab's leadership, and employee representatives attended the listing ceremony, jointly witnessing this milestone moment.

Trinomab is dedicated to alternative therapies for blood products. Relying on its proprietary "High-throughput Fully Human Monoclonal Antibody R&D Comprehensive Technology Platform HitmAb" and other technical platforms, the company continuously explores the potential for higher safety and efficacy in antibody drugs within the field of fully human monoclonal antibodies. It has successfully developed multiple antibody molecules as drug candidates, covering disease areas such as infectious diseases and pain management.

In addition to the commercialized anti-tetanus monoclonal antibody—Siltartoxatug Injection, which builds the foundation of the company's performance, Trinomab's multi-layered and in-depth R&D pipeline establishes a second growth curve for the company's long-term value appreciation. Another core product, the recombinant long-acting fully human monoclonal antibody against Respiratory Syncytial Virus (RSV)—Retavibart Injection (previously named TNM001), has had its New Drug Application (NDA) accepted and included in the priority review program. It has also been granted funding under the National Science and Technology Major Project. With national strategic support, the company deepens independent innovation to tackle the core challenge of RSV protection for infants. Phase III clinical study results show that a single intramuscular injection significantly reduces the incidence of RSV-induced lower respiratory tract infections in healthy full-term and late preterm infants, providing sustained protection for up to 270 days after injection—far exceeding the typical 150-day RSV season. Furthermore, the anti-Nerve Growth Factor (NGF) monoclonal antibody TNM009 and the anti-Varicella-Zoster Virus (VZV) monoclonal antibody TNM005 have completed Phase I clinical trials, with an additional 3 drug candidates in the preclinical stage.

From exploring the uncharted territory of global recombinant anti-tetanus monoclonal antibodies to the shining moment of today's listing on the STAR Market, ten years of deep cultivation represents an innovation marathon to safeguard patients. Standing at this new capital starting point, Trinomab will continue to unleash innovative value, transforming cutting-edge biopharmaceutical technologies from the laboratory into accessible, high-quality therapies that truly benefit a vast number of patients!

Mr. Su Yuexing, Crystal-Ambio Capital:

As a staunch partner who has invested in Trinomab multiple times consecutively, we are deeply honored to witness this milestone moment.

Trinomab possesses core full-chain capabilities ranging from source discovery to GMP production and commercial sales, based on its fully human antibody technology platform. This significantly enhances the efficiency, success rate, and replicability of its innovative product R&D. Leveraging this original technology platform, the company is riding the definitive industrial upgrade trend of "recombinant monoclonal antibodies replacing traditional blood products." Its core product, Siltartoxatug Injection, as the world's first anti-tetanus monoclonal antibody, has been approved for listing, thoroughly resolving clinical pain points such as blood source shortages and allergic risks. Following its inclusion in the national medical insurance catalog, we are delighted to see a substantial increase in the number of hospitals developed, which demonstrates Trinomab's even more valuable commercialization capabilities. Meanwhile, we are highly optimistic about the company's other core product, TNM001 (generic name: Retavibart Injection), which focuses on the massive unmet need for infant RSV prevention and holds vast market prospects.

Congratulations to Trinomab on its successful listing on the STAR Market! We look forward to "global innovation from China" stepping onto the "world stage" and benefiting global patients at an early date.

Dr. Liao Huaxin, Chairman and CTO of Trinomab:

For a long time, domestic passive immunization preparations have relied heavily on plasma raw materials. Constrained by plasma resources, the supply of several clinically essential immunoglobulins has remained tight—a pain point that the industry has struggled to resolve for years. Our original intention in starting the business was to address this pain point and unmet clinical needs, and to cultivate innovative drugs with independent innovation as our core.

Now that Trinomab has successfully listed on the STAR Market, empowered by capital to accelerate technological iteration and product commercialization, we are confident that we will use source innovation to reshape the new landscape of the domestic passive immunization industry!

Mr. Zheng Weihong, Vice Chairman and General Manager of Trinomab:

After entering the capital market, Trinomab will take the STAR Market as a new starting point. We will remain true to our original aspiration, always adhering to the mission of "creating clinical value," accelerating the global R&D, production, and commercialization layout of core products, and continuously improving corporate governance.

We will focus on building products based on clinical needs, realizing a virtuous development ecosystem where Trinomab's sustainable development and shareholder returns grow synergistically. We aim to repay the investors who trust us with steady operational results and benefit patients at home and abroad with high-quality innovative products.

Disclaimer

1.Trinomab does not recommend any drugs that have not been approved for listing or indications that have not been approved.

2.The medical information in this press release is for informational popularization and news reporting purposes only. It does not constitute medical advertising, nor does it constitute any form of diagnosis and treatment advice, medication guidance, or doctor-patient communication. No individual or institution shall use it for commercial promotion or medical decision-making.

Forward-Looking Statements

The information contained in this press release is as of the date of release. The information released in this press release may contain certain forward-looking statements. These statements are inherently subject to substantial risks and uncertainties. When using words such as "expect," "believe," "predict," "expect," "intend," and other similar expressions, any statements related to the Company are intended to identify them as forward-looking statements. The Company has no obligation to update these predictive statements, regardless of the emergence of new information, future events, or new developments.